Journal of Clinical & Experimental Pharmacology

A biochemical and histomorphometric study of the potential anabolic and antiresorptive effects of methionine amino acid on ovariectomy induced osteoporosis in rats

3^rd World Congress on Pharmacology

August 08-10, 2016 Birmingham, UK

Sahar Ahmed Harby

Alexandria University Faculty of Medicine, Egypt

Posters & Accepted Abstracts: Clin Exp Pharmacol

Abstract:

Osteoporosis is a growing public health problem in both developed and developing countries, particularly among postmenopausal women. The seriousness of the disease comes from the increased risk of fracture, increasing with age. Most of established osteoporosis pharmacological treatments are associated with risky side effects, for example ulcer and renal toxicity with bisphosphonates, and cardiovascular complications with hormone replacement therapy. Therefore, development of safer prophylactic and treatment strategies is needed. This study aims at assessing the effect of methionine on ovariectomized rat model of postmenopausal osteoporosis. Female albino rats were divided into four groups: (I) sham rats (normal control), (II) ovariectomized (osteoporosis control), (III) ovariectomized + alendronate 0.1 mg/kg orally daily for 8 weeks, (IV) ovariectomized + methionine 250 mg/kg orally daily for 8 weeks. Serum osteocalcin and tartrate-resistant acid phosphatase 5b (TRAP5b) were determined. Histomorphometric measurement of trabecular and cortical bone thickness was done and analyzed. Treatment of ovariectomized rats with methionine produced both anabolic and antiresorptive effects on bone. The anabolic effect was evidenced by histological signs of bone formation and histomorphometric analysis revealing increased bone thickness compared to group II and III. The significantly lower serum TRAP5b compared to group II and histomorphometric analysis evidenced the antiresorptive effect. The results of our study suggested potential anabolic and antiresorptive effects of methionine in postmenopausal osteopororsis. However, further studies on the efficacy as well as safety of methionine treatment in postmenopausal osteopororsis in human and comparing it with the only approved, until now, bone anabolic drug, teriparatide, is recommended.

Biography :

Email: sahar_ahmed_900900@linkedin.com